Italia - italiano - Ministero della Salute

certiplant nv - diquat (dibromide); - concentrato solubile - 17.0 g i valori indicati sono per 100 g di prodotto. - diserbante

Italia - italiano - Ministero della Salute

certis europe b.v. - 1,3-dichloropropene; - concentrato emulsionabile - 92.5 g i valori indicati sono per 100 g di prodotto. - nematocida

Italia - italiano - Ministero della Salute

certis europe b.v. - piretrine; - concentrato emulsionabile - 4.27 g i valori indicati sono per 100 g di prodotto. - insetticida

Unione Europea - italiano - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. l'effetto di imatinib sull'esito del trapianto di midollo osseo non è stata determinata. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. l'esperienza con imatinib in pazienti con mds/mpd associate a riarrangiamenti del gene pdgfr è molto limitata. non ci sono studi clinici controllati che dimostrano un beneficio clinico o un aumento della sopravvivenza per queste malattie.

Italia - italiano - Ministero della Salute

piaubert -

Italia - italiano - Ministero della Salute

jeanne piaubert -

Italia - italiano - Ministero della Salute

jeanne piaubert -

Italia - italiano - Ministero della Salute

piaubert -

Italia - italiano - Ministero della Salute

piaubert -

Italia - italiano - Ministero della Salute

piaubert -